Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22503881 | 0.89 | MAPK14 (0.35) | MAPK14 | |
| SCHEMBL19115750 | 0.87 | MAPK14 (0.33) | MAPK14 | |
| SCHEMBL16013097 | 0.78 | MAPK14 (0.40) | MAPK14ADRA1AADRA1BCA2ALDH1A1 | |
| SCHEMBL16637599 | 0.77 | MAPK14 (0.39) | MAPK14ADRA1AADRA1BCA2ALDH1A1 | |
| SCHEMBL17925137 | 0.77 | MAPK14 (0.39) | MAPK14ADRA1AADRA1BCA2ALDH1A1 | |
| SCHEMBL7964858 | 0.75 | ADRA1B (0.49) | MAPK14ADRA1AADRA1BTMEM97SIGMAR1 | |
| SCHEMBL2215555 | 0.74 | MAPK14 (0.43) | MAPK14ADRA1AADRA1BCA2ALDH1A1 | |
| SCHEMBL5766219 | 0.74 | MAPK14 (0.43) | MAPK14ADRA1AADRA1BCA2ALDH1A1 | |
| SCHEMBL12012111 | 0.73 | NFE2L2 (0.47) | MAPK14ADRA1BCA2HTR1AADRA1D | |
| SCHEMBL13064749 | 0.72 | MAPK14 (0.44) | MAPK14ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3608308-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-10-06 | — | — | US | disclosed |
| US-10729775-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-08-04 | — | — | US | disclosed |
| EP-3608308-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2020-02-12 | — | — | EP | disclosed |
| EP-2964608-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2019-08-28 | — | — | EP | disclosed |
| EP-2964608-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2019-08-28 | — | — | EP | disclosed |
| US-20180369386-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-12-27 | — | — | US | disclosed |
| US-10124065-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2018-11-13 | — | — | US | disclosed |
| US-20170196979-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-20170196979-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-9504747-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2016-11-29 | — | — | US | disclosed |
| US-9504747-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2016-11-29 | — | — | US | disclosed |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | disclosed |
| EP-2964608-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20140303232-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| US-20140303232-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| WO-2014136086-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10124065-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | MAPK14 3804/4885ADRA1A 788/4885ADRA1B 1094/4885 |
| US-20180369386-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | MAPK14 3804/4885ADRA1A 788/4885ADRA1B 1094/4885 |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | MAPK14 3804/4885ADRA1A 788/4885ADRA1B 1094/4885 |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | MAPK14 3804/4885ADRA1A 788/4885ADRA1B 1094/4885 |
| US-20140303232-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | MAPK14 3804/4885ADRA1A 788/4885ADRA1B 1094/4885 |
| US-10729775-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | MAPK14 3804/4885ADRA1A 788/4885ADRA1B 1094/4885 |
| US-20170196979-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | MAPK14 3804/4885ADRA1A 788/4885ADRA1B 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.